Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

33.43 -0.01 (-0.03%)
Official Closing Price Updated: 4:10 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
Activist Hedge Fund Elliott Questions GSK CEO Walmsley's Leadership: Mail on Sunday
GlaxoSmithKline Plc (NYSE: GSK) appeared to dodge a potential shakeup last week when Elliott Management said it would not push the sale of its vaccines and... 
Via Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
Right now, GlaxoSmithKline Inc. (NYSE:GSK) share price is at $38.53, after a 0.62% drop. Over the past month, the stock spiked by 2.75%, but over the past year, it... 
Via Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... 
Via Benzinga
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
Exposures COVID-19
2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now
These pharmaceutical companies might make great long-term additions to your portfolio. 
Via The Motley Fool
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Activist Hedge Fund Elliott Management Backs Away from Forced GlaxoSmithKline's Vaccines, Pharma Business Sale: The Times
The Times of London reports that activist investor Paul Singer's hedge fund Elliott Management will not push the sale of GlaxoSmithKline Plc’s (NYSE... 
Via Benzinga
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ... 
Via Benzinga
Exposures COVID-19 Product Safety
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, May 27
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability. 
Via Talk Markets
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion
The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir... 
Via Benzinga
Exposures COVID-19
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
GSK Exits Respiratory Partner Innoviva In $392M Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392... 
Via Benzinga
Cramer Shares His Thoughts On Marvell, MicroVision, More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Cerence Inc (NASDAQ: CRNC) is just one more software company. He doesn't want to play. Cramer wants great... 
Via Benzinga
Better Buy for 2021: GlaxoSmithKline or Sanofi?
These are two cheap stocks in an overvalued market. 
Via The Motley Fool
May Or May Not Happen
Another day, another drop. 
Via Talk Markets
GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response
Interim Phase 2 trial results of GlaxoSmithKline plc (NYSE: GSK) and its collaborating partner Medicago Inc’s COVID-19 vaccine candidate showed... 
Via Benzinga
Exposures COVID-19
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of... 
Via Benzinga
Exposures COVID-19
73 Firms Going Ex-Dividend Next Week, Including Target, Hershey And GlaxoSmithKline
Several well known large cap stocks go ex-dividend next week including the following: Con Ed, Aflac, Target, Chevron, Eversource Energy, Magna International, Hershey Company, Walgreens Boots Alliance,... 
Via Talk Markets
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-... 
Via Benzinga
Exposures COVID-19
A Down Day
The tech wreck continues because inflation will hurt the costly stock sector more than others. 
Via Talk Markets
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.